Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03289273 · ClinicalTrials.gov registry record
Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 1,010
- Enrollment target
NCT03289273: Completed study, sponsored by Bayer.
NCT03289273 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 1,010 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03289273 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 1,010 participants
- Enrollment target
Study Summary
Observational study to evaluate, under real-world practice conditions, the safety and effectiveness of regorafenib in patients diagnosed with unresectable hepatocellular carcinoma (uHCC)
Primary Outcome
The primary endpoint is the safety of regorafenib in patients with uHCC, defined as the frequency of documented TEAEs, including serious adverse events (SAEs). Safety will be assessed in all patients who receive at least one dose of regorafenib regardless of prior treatment.
Interventions
- DRUG Regorafenib (Stivarga, BAY73-4506)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,010 participants |
| Start Date | 2017-09-13 |
| Est. Completion | 2022-06-21 |
What the finished NCT03289273 record still lists
NCT03289273 is an observational study that tracks outcomes without assigning an intervention. Its 1,010 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Regorafenib (Stivarga, BAY73-4506) is the first listed.
NCT03289273 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03289273 about?
NCT03289273 is a clinical study titled "Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)". Observational study to evaluate, under real-world practice conditions, the safety and effectiveness of regorafenib in patients diagnosed with unresectable hepatocellular carcinoma (uHCC)
What is the current status of trial NCT03289273?
This trial is currently completed. The enrollment target is 1,010 participants. The study started on 2017-09-13. Estimated completion is 2022-06-21.
What interventions are being tested in trial NCT03289273?
The interventions under investigation include: Regorafenib (Stivarga, BAY73-4506) (DRUG).
Who is sponsoring clinical trial NCT03289273?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07191782 · 1,008 participants · NA
Examining the Efficacy of the PRAISE With Coaching Program
- NCT04389632 · 1,006 participants · Phase 1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- NCT06146738 · 1,015 participants
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
- NCT06608823 · 1,016 participants · NA
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI